Cutaneous T-Cell Lymphoma

Targretin cutaneous T-cell lymphoma therapy reimbursed by Medicare

Published in Blood Weekly, July 29th, 2004

Ligand Pharmaceuticals Incorporated (LGND) reported that the U.S. Centers for Medicare and Medicaid Services' (CMS) recently announced formal implementation of the Section 641 Demonstration Program under the Medicare Modernization Act of 2003 includes reimbursement under Medicare for Targretin (bexarotene) for patients with cutaneous T-cell lymphoma (CTCL).

This demonstration program initiates coverage for selected self-administered drugs and biologics, including Targretin, under Medicare almost 18 months earlier than Medicare Part D, which will initiate reimbursement for most prescription drugs in January 2006.

"This is an important program for...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2004-07-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry